Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA versus ALLEGRA ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA versus ALLEGRA ALLERGY.
ALLEGRA vs ALLEGRA ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.
60 mg orally twice daily or 180 mg orally once daily.
Fexofenadine 180 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours in healthy adults, allowing for twice-daily dosing. In patients with renal impairment, half-life may be prolonged (up to 59 hours in severe impairment).
Terminal elimination half-life is 14.4 hours (range 8–16 hours) in healthy adults. In renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for the majority of fecal elimination. Renal elimination is minimal due to extensive tubular reabsorption.
Primarily eliminated in feces (80%) and urine (approximately 15%) as unchanged drug. Biliary secretion contributes significantly.
Category C
Category C
Antihistamine (Nonsedating)
Antihistamine (Nonsedating)